BioLight Life Sciences
2234 Street, Building 7, 2nd floor, Kiryat Atidim, Tel Aviv, 6158101, Israel
Overview
BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects relating to eye disease and their treatment. BioLight’s portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine and all exemplify the enormous potential of Israeli innovation in these fields. Development and commercialization of the company’s ophthalmic technologies and products. The ophthalmic products developed by the companies in the BioLight group are aimed at innovative diagnosis and treatments for the needs of patient groups suffering from eye diseases. The different ophthalmic products are in various commercialization and clinical (or pre-clinical) phases. BioLight intends, in line with its financial capabilities, to continue supplementing and expanding the array of technologies and products under development, whether through investment in additional companies or through business development and expansion of the activity of the existing companies.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 3
Sector focus
- Biotechnology
- Health Care
- Health Diagnostics
- Life Science
Investment portfolio
- BELKIN Vision
Participated · Series B · Jul 2020
Belkin Laser develops an automated, non-contact, painless laser treatment for glaucoma that is activated by a touchscreen and controlled by a high-resolution image acquisition algorithm and a proprietary eye tracker. The technology, originated by Prof. Michael Belkin and led by CEO Daria Lemann-Blumenthal, is designed to be used by all ophthalmologists to increase treated patient volumes in both central and rural areas and to open a new revenue stream for clinics and hospitals. The company closed a $12.25M Series B and intends to use the funds to continue GLAUrious, its multi-center trial in Europe, and to initiate trials in Asia. Prior to the Series B, Belkin had raised $6.6M, which included an Israel Innovation Authority incubator grant at the Rad Biomed Accelerator and a $3M European Horizon 2020 grant. The company also raised an additional $2.5M as part of a Series A financing led by ZIG Ventures from Singapore. No operational metrics or valuation were disclosed in the article.